Lineage Cell Therapeutics (LCTX) Amortizatization of Intangibles (2014 - 2022)
Lineage Cell Therapeutics' (LCTX) quarterly Amortizatization of Intangibles came in at -$3000.0 in Q2 2022, down 130.0% year-on-year from $10000.0 in Q2 2021, and up 25.0% quarter-over-quarter from -$4000.0 in Q1 2022.
Lineage Cell Therapeutics (LCTX) Amortizatization of Intangibles (2014 - 2022) Analysis & Trends
Lineage Cell Therapeutics' Amortizatization of Intangibles history runs 8 years deep, the most recent figure standing at -$3000.0 for Q2 2022.
- On a quarterly basis, Amortizatization of Intangibles fell 130.0% year-over-year to -$3000.0 in Q2 2022; TTM through Jun 2022 was -$13000.0, a 117.57% decrease from a year earlier, with the FY2021 full-year figure at $14000.0, down 80.56% from the prior year.
- Amortizatization of Intangibles climbed to -$3000.0 in Q2 2022 per LCTX's latest filing, from -$4000.0 in the prior quarter.
- Across five years, Amortizatization of Intangibles topped out at $70000.0 in Q4 2019 and bottomed at -$5000.0 in Q4 2021.
- The 4-year median for Amortizatization of Intangibles is $10000.0 (2021), against an average of $14857.1.
- Across the five-year window, Amortizatization of Intangibles rose 11.11% in 2021 and plunged 140.0% in 2022, its largest moves.
- Year by year, Amortizatization of Intangibles stood at $70000.0 in 2019, then plunged by 64.29% to $25000.0 in 2020, then sank by 120.0% to -$5000.0 in 2021, then surged by 40.0% to -$3000.0 in 2022.
- Per Business Quant, the three latest LCTX Amortizatization of Intangibles figures stand at -$3000.0 (Q2 2022), -$4000.0 (Q1 2022), and -$5000.0 (Q4 2021).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Amortizatization of Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | - |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | - |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | 3.22 Mn |
| 10 | Lineage Cell Therapeutics | 254.83 Mn | 192.11 Mn | 1.73 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2022 | -3,000.00 |
| Jun 30, 2022 | -3,000.00 |
| Mar 31, 2022 | -4,000.00 |
| Mar 31, 2022 | -4,000.00 |
| Dec 31, 2021 | -5,000.00 |
| Dec 31, 2021 | -5,000.00 |
| Sep 30, 2021 | -1,000.00 |
| Sep 30, 2021 | -1,000.00 |
| Jun 30, 2021 | 10,000.00 |
| Jun 30, 2021 | 10,000.00 |
| Mar 31, 2021 | 10,000.00 |
| Mar 31, 2021 | 10,000.00 |
| Dec 31, 2020 | 25,000.00 |
| Dec 31, 2020 | 25,000.00 |
| Sep 30, 2020 | 29,000.00 |
| Sep 30, 2020 | 29,000.00 |
| Jun 30, 2020 | 9,000.00 |
| Jun 30, 2020 | 9,000.00 |
| Mar 31, 2020 | 9,000.00 |
| Mar 31, 2020 | 9,000.00 |